Analyst Consensus ?
ConsensusBuy41 ratings
Bullish3585.4%
Neutral614.6%
Bearish00.0%
FN2 Earnings Intelligence
CVS Health Corp. (CVS) analyst consensus, price targets, and firm-level rating history from FN2 Research.
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 29, 2026. Not an FN2 forecast.
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| UBS | Buy | Buy | Maintain | Jul 24, 2026 |
| Truist Securities | Buy | Buy | Maintain | Jul 14, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Jul 13, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Jul 9, 2026 |
| Cantor Fitzgerald | Overweight | Overweight | Maintain | Jul 7, 2026 |
| B of A Securities | Buy | Buy | Maintain | Jun 23, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Jun 8, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Jun 4, 2026 |
| Barclays | Overweight | Overweight | Maintain | May 26, 2026 |
| Bernstein | Outperform | Outperform | Maintain | May 13, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | May 12, 2026 |
| TD Cowen | Buy | Buy | Maintain | May 11, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | May 7, 2026 |
| Baird | Outperform | Outperform | Maintain | Apr 15, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Mar 31, 2026 |
| Argus Research | Buy | Buy | Maintain | Jan 28, 2026 |
| Jefferies | Buy | Buy | Maintain | Jun 30, 2025 |
| Leerink Partners | Outperform | Market Perform | Upgrade | Feb 13, 2025 |
| Deutsche Bank | Buy | Hold | Upgrade | Dec 3, 2024 |
| Goldman Sachs | Buy | Buy | Maintain | May 2, 2024 |
| Wolfe Research | Outperform | Peer Perform | Upgrade | Sep 12, 2023 |
| Edward Jones | Hold | Buy | Downgrade | Aug 18, 2023 |
| Raymond James | Outperform | Outperform | Maintain | Aug 4, 2023 |
| Credit Suisse | Outperform | Outperform | Maintain | May 8, 2023 |
| Tigress Financial | Buy | Buy | Maintain | Dec 23, 2021 |
| BMO Capital | Market Perform | Market Perform | Maintain | May 19, 2021 |
| Guggenheim | Neutral | Buy | Downgrade | Mar 17, 2021 |
| SVB Leerink | Market Perform | Market Perform | Maintain | Dec 14, 2020 |
| Citigroup | Buy | Buy | Maintain | May 7, 2020 |
| SunTrust Robinson Humphrey | Buy | Buy | Maintain | Apr 13, 2020 |
| CFRA | Strong Buy | Strong Buy | Maintain | Feb 13, 2020 |
| Citi | Buy | Buy | Maintain | Nov 7, 2019 |
| Bank of America | Buy | Buy | Maintain | Sep 12, 2019 |
| Oppenheimer | Perform | Outperform | Downgrade | Apr 15, 2019 |
| Leerink Swann | Outperform | Outperform | Maintain | Feb 9, 2018 |
| Needham | Buy | Hold | Upgrade | Nov 10, 2017 |
| Loop Capital | Hold | Hold | Maintain | Nov 7, 2017 |
| Cowen & Co. | Outperform | Outperform | Maintain | Jun 10, 2015 |
| FBR Capital | Outperform | Outperform | Maintain | Nov 5, 2014 |
| ISI Group | Strong Buy | Buy | Upgrade | Jan 22, 2014 |
| Macquarie | Outperform | Neutral | Upgrade | Dec 14, 2012 |
Upside is calculated against the persisted current price $109.34. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Analyst unavailable | $122 | $107.85 | +11.6% | Jul 24, 2026 |
| Truist Financial | David MacDonald | $118 | $105.9 | +7.9% | Jul 14, 2026 |
| Wells Fargo | Analyst unavailable | $123 | $104.15 | +12.5% | Jul 13, 2026 |
| RBC Capital | Analyst unavailable | $113 | $104.83 | +3.3% | Jul 9, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $110 | $102.08 | +0.6% | Jul 7, 2026 |
| HSBC | Analyst unavailable | $103 | $102.28 | -5.8% | Jul 6, 2026 |
| Mizuho Securities | Analyst unavailable | $115 | $95.93 | +5.2% | Jun 8, 2026 |
| Morgan Stanley | Analyst unavailable | $111 | $91.37 | +1.5% | Jun 4, 2026 |
| Truist Financial | Analyst unavailable | $108 | $90.98 | -1.2% | Jun 1, 2026 |
| Piper Sandler | Jessica Tassan | $113 | $90.98 | +3.3% | Jun 1, 2026 |
| Barclays | Andrew Mok | $106 | $91.63 | -3.1% | May 26, 2026 |
| Mizuho Securities | Analyst unavailable | $110 | $94.18 | +0.6% | May 20, 2026 |
| Morgan Stanley | Analyst unavailable | $106 | $97.85 | -3.1% | May 14, 2026 |
| Bernstein | Analyst unavailable | $106 | $95.15 | -3.1% | May 13, 2026 |
| RBC Capital | Analyst unavailable | $107 | $86.56 | -2.1% | May 7, 2026 |
| Deutsche Bank | Analyst unavailable | $92 | $87.46 | -15.9% | May 7, 2026 |
| Truist Financial | Analyst unavailable | $102 | $87.04 | -6.7% | May 7, 2026 |
| Barclays | Andrew Mok | $101 | $86.86 | -7.6% | May 7, 2026 |
| Robert W. Baird | Analyst unavailable | $94 | $77.62 | -14.0% | Apr 15, 2026 |
| Leerink Partners | Michael Cherny | $98 | $79.49 | -10.4% | Mar 5, 2026 |
| Argus Research | Analyst unavailable | $90 | $73.2 | -17.7% | Jan 28, 2026 |
| Bernstein | Analyst unavailable | $91 | $80.56 | -16.8% | Jan 6, 2026 |
| Bernstein | Analyst unavailable | $87 | $80.84 | -20.4% | Dec 12, 2025 |
| Mizuho Securities | Ann Hynes | $95 | $79.05 | -13.1% | Dec 10, 2025 |
| Robert W. Baird | Analyst unavailable | $92 | $78.24 | -15.9% | Dec 10, 2025 |
| Piper Sandler | Jessica Tassan | $101 | $78.24 | -7.6% | Dec 10, 2025 |
| Morgan Stanley | Analyst unavailable | $93 | $78.24 | -14.9% | Dec 10, 2025 |
| Barclays | Analyst unavailable | $93 | $78.24 | -14.9% | Dec 10, 2025 |
| UBS | Kevin Caliendo | $97 | $78.24 | -11.3% | Dec 10, 2025 |
| Truist Financial | Analyst unavailable | $100 | $78.24 | -8.5% | Dec 10, 2025 |
| Bernstein | Analyst unavailable | $86 | $76.75 | -21.3% | Dec 4, 2025 |
| RBC Capital | Analyst unavailable | $93 | $77.56 | -14.9% | Oct 30, 2025 |
| UBS | Analyst unavailable | $96 | $81.07 | -12.2% | Oct 24, 2025 |
| Truist Financial | David MacDonald | $92 | $79.26 | -15.9% | Oct 14, 2025 |
| Morgan Stanley | Erin Wright | $89 | $78.82 | -18.6% | Oct 14, 2025 |
| Goldman Sachs | Analyst unavailable | $91 | $78.44 | -16.8% | Oct 14, 2025 |
| Mizuho Securities | Ann Hynes | $88 | $76.93 | -19.5% | Oct 9, 2025 |
| Wells Fargo | Analyst unavailable | $103 | $76.84 | -5.8% | Oct 7, 2025 |
| Barclays | Andrew Mok | $87 | $73.32 | -20.4% | Sep 4, 2025 |
| UBS | Kevin Caliendo | $79 | $68.6 | -27.7% | Aug 18, 2025 |
| Robert W. Baird | Michael Ha | $82 | $66.58 | -25.0% | Aug 14, 2025 |
| Barclays | Andrew Mok | $79 | $63.6 | -27.7% | Jun 2, 2025 |
| Argus Research | Analyst unavailable | $77 | $65.57 | -29.6% | Feb 18, 2025 |
| Deutsche Bank | George Hill | $66 | $59.08 | -39.6% | Dec 3, 2024 |
| Wells Fargo | Stephen Baxter | $66 | $57.11 | -39.6% | Nov 18, 2024 |
| Mizuho Securities | Ann Hynes | $66 | $57.04 | -39.6% | Oct 24, 2024 |
| Truist Financial | David MacDonald | $76 | $58.2 | -30.5% | Oct 21, 2024 |
| Piper Sandler | Jessica Tassan | $72 | $59.15 | -34.2% | Oct 21, 2024 |
| Barclays | Andrew Mok | $82 | $66.63 | -25.0% | Oct 10, 2024 |
| Deutsche Bank | George Hill | $63 | $57.85 | -42.4% | Aug 8, 2024 |
| J.P. Morgan | Lisa Gill | $86 | $58.58 | -21.3% | Jun 28, 2024 |
| Barclays | Andrew Mok | $65 | $61.01 | -40.6% | Jun 20, 2024 |
| RBC Capital | Anton Hie | $68 | $56.31 | -37.8% | May 2, 2024 |
| Piper Sandler | Jessica Tassan | $94 | $77.4 | -14.0% | Mar 15, 2024 |
| Morgan Stanley | Erin Wright | $100 | $73.76 | -8.5% | Dec 12, 2023 |
| Truist Financial | David Macdonald | $98 | $70.52 | -10.4% | Sep 13, 2023 |
| Wolfe Research | Justin Lake | $80 | $70.52 | -26.8% | Sep 12, 2023 |
| Truist Financial | David Macdonald | $103 | $71.27 | -5.8% | Jul 12, 2023 |
| Morgan Stanley | Analyst unavailable | $120 | $89.18 | +9.7% | Jan 13, 2023 |
| Wells Fargo | Analyst unavailable | $101 | $92.91 | -7.6% | Jan 3, 2023 |
| Evercore ISI | Analyst unavailable | $100 | $93.19 | -8.5% | Jan 3, 2023 |
| Morgan Stanley | Analyst unavailable | $119 | $100.22 | +8.8% | Nov 23, 2022 |
| Evercore ISI | Analyst unavailable | $125 | $100.52 | +14.3% | Sep 7, 2022 |
| Mizuho Securities | Analyst unavailable | $120 | $106.39 | +9.7% | Aug 15, 2022 |
| Deutsche Bank | George Hill | $120 | $106.39 | +9.7% | Aug 14, 2022 |
| Credit Suisse | Analyst unavailable | $117 | $102.26 | +7.0% | Aug 8, 2022 |
| UBS | Analyst unavailable | $127 | $103.14 | +16.2% | Aug 4, 2022 |
| Deutsche Bank | Analyst unavailable | $113 | $97.73 | +3.3% | May 5, 2022 |
| Tigress Financial | Ivan Feinseth | $125 | $104.45 | +14.3% | Apr 11, 2022 |
| Deutsche Bank | George Hill | $110 | $102.13 | +0.6% | Feb 21, 2022 |
| BMO Capital | Matt Borsch | $120 | $104.24 | +9.7% | Feb 13, 2022 |
| Goldman Sachs | Nathan Rich | $121 | $104.79 | +10.7% | Feb 9, 2022 |
| RBC Capital | Ben Hendrix | $119 | $104.79 | +8.8% | Feb 9, 2022 |
| Jefferies | Brian Tanquilut | $120 | $102.39 | +9.7% | Jan 20, 2022 |
| Bank of America Securities | Michael Cherny | $117 | $106.22 | +7.0% | Jan 16, 2022 |
| Bernstein | Lance Wilkes | $116 | $105.48 | +6.1% | Jan 11, 2022 |
| Wells Fargo | Steve Baxter | $111 | $102.04 | +1.5% | Jan 6, 2022 |
| Truist Financial | David S Macdonald | $124 | $105.25 | +13.4% | Jan 5, 2022 |
| Morgan Stanley | Ricky Goldwasser | $125 | $98.37 | +14.3% | Dec 13, 2021 |
| Cowen & Co. | Charles Rhyee | $114 | $98.33 | +4.3% | Dec 10, 2021 |
| Credit Suisse | A.J. Rice | $120 | $98.33 | +9.7% | Dec 10, 2021 |
| Seaport Global | Joseph France | $110 | $88.31 | +0.6% | Dec 1, 2021 |
| UBS | Kevin Caliendo | $106 | $93.71 | -3.1% | Nov 11, 2021 |
| Cantor Fitzgerald | Steven Halper | $115 | $95.83 | +5.2% | Nov 3, 2021 |
| Wolfe Research | Justin Lake | $93 | $87.69 | -14.9% | May 19, 2021 |
Track every rating change on CVS the moment it posts. Free to start.
Start free